214 related articles for article (PubMed ID: 21864238)
41. Anticancer Activity of Alkynylgold(I) with P(NMe
Abas E; Espallargas N; Burbello G; Mesonero JE; Rodriguez-Dieguez A; Grasa L; Laguna M
Inorg Chem; 2019 Nov; 58(22):15536-15551. PubMed ID: 31697068
[TBL] [Abstract][Full Text] [Related]
42. New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one?
Wenzel M; Bigaeva E; Richard P; Le Gendre P; Picquet M; Casini A; Bodio E
J Inorg Biochem; 2014 Dec; 141():10-16. PubMed ID: 25172993
[TBL] [Abstract][Full Text] [Related]
43. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
44. Highly cytotoxic bioconjugated gold(I) complexes with cysteine-containing dipeptides.
Gutiérrez A; Marzo I; Cativiela C; Laguna A; Gimeno MC
Chemistry; 2015 Jul; 21(31):11088-95. PubMed ID: 26111275
[TBL] [Abstract][Full Text] [Related]
45. Alkynyl gold(I) phosphane complexes: Evaluation of structure-activity-relationships for the phosphane ligands, effects on key signaling proteins and preliminary in-vivo studies with a nanoformulated complex.
Andermark V; Göke K; Kokoschka M; Abu El Maaty MA; Lum CT; Zou T; Sun RW; Aguiló E; Oehninger L; Rodríguez L; Bunjes H; Wölfl S; Che CM; Ott I
J Inorg Biochem; 2016 Jul; 160():140-8. PubMed ID: 26850306
[TBL] [Abstract][Full Text] [Related]
46. Cancer molecular biology and strategies for the design of cytotoxic gold(I) and gold(III) complexes: a tutorial review.
van der Westhuizen D; Bezuidenhout DI; Munro OQ
Dalton Trans; 2021 Dec; 50(47):17413-17437. PubMed ID: 34693422
[TBL] [Abstract][Full Text] [Related]
47. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
48. N(4)-tolyl-2-acetylpyridine thiosemicarbazones and their platinum(II,IV) and gold(III) complexes: cytotoxicity against human glioma cells and studies on the mode of action.
Ferraz KS; Da Silva JG; Costa FM; Mendes BM; Rodrigues BL; dos Santos RG; Beraldo H
Biometals; 2013 Oct; 26(5):677-91. PubMed ID: 23749148
[TBL] [Abstract][Full Text] [Related]
49. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.
Altaf M; Monim-Ul-Mehboob M; Kawde AN; Corona G; Larcher R; Ogasawara M; Casagrande N; Celegato M; Borghese C; Siddik ZH; Aldinucci D; Isab AA
Oncotarget; 2017 Jan; 8(1):490-505. PubMed ID: 27888799
[TBL] [Abstract][Full Text] [Related]
50. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.
Wang X; Guo Z
Dalton Trans; 2008 Mar; (12):1521-32. PubMed ID: 18335133
[TBL] [Abstract][Full Text] [Related]
51. Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes.
McKeage MJ; Berners-Price SJ; Galettis P; Bowen RJ; Brouwer W; Ding L; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2000; 46(5):343-50. PubMed ID: 11127937
[TBL] [Abstract][Full Text] [Related]
52. Amides of gold(I) diphosphines prepared from N-heterocyclic sources and their in vitro and in vivo screening for anticancer activity.
Horvath UE; Dobrzańska L; Strasser CE; Bouwer Neé Potgieter W; Joone G; van Rensburg CE; Cronje S; Raubenheimer HG
J Inorg Biochem; 2012 Jun; 111():80-90. PubMed ID: 22498717
[TBL] [Abstract][Full Text] [Related]
53. Antiproliferative activity exerted by tricyclohexylphosphanegold(I) n-mercaptobenzoate against MCF-7 and A2780 cell lines: the role of p53 signaling pathways.
Ang KP; Chan PF; Hamid RA
Biometals; 2021 Feb; 34(1):141-160. PubMed ID: 33196940
[TBL] [Abstract][Full Text] [Related]
54. Metal complexes, their cellular targets and potential for cancer therapy.
Chen D; Milacic V; Frezza M; Dou QP
Curr Pharm Des; 2009; 15(7):777-91. PubMed ID: 19275642
[TBL] [Abstract][Full Text] [Related]
55. Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Quero J; Cabello S; Fuertes T; Mármol I; Laplaza R; Polo V; Gimeno MC; Rodriguez-Yoldi MJ; Cerrada E
Inorg Chem; 2018 Sep; 57(17):10832-10845. PubMed ID: 30117739
[TBL] [Abstract][Full Text] [Related]
56. Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.
Sze JH; Raninga PV; Nakamura K; Casey M; Khanna KK; Berners-Price SJ; Di Trapani G; Tonissen KF
Redox Biol; 2020 Jan; 28():101310. PubMed ID: 31514052
[TBL] [Abstract][Full Text] [Related]
57. Deubiquitinases as potential anti-cancer targets for gold(III) complexes.
Zhang JJ; Ng KM; Lok CN; Sun RW; Che CM
Chem Commun (Camb); 2013 Jun; 49(45):5153-5. PubMed ID: 23629480
[TBL] [Abstract][Full Text] [Related]
58. Synthesis of thionato(triethylphosphine) gold(I) complexes:analogues of "auranofin," an antiarthritic drug.
Isab AA; Shaw CF
J Inorg Biochem; 1990 Feb; 38(2):95-100. PubMed ID: 1969932
[TBL] [Abstract][Full Text] [Related]
59. Studies on the Interaction between Poly-Phosphane Gold(I) Complexes and Dihydrofolate Reductase: An Interplay with Nicotinamide Adenine Dinucleotide Cofactor.
Pucciarelli S; Vincenzetti S; Ricciutelli M; Simon OC; Ramadori AT; Luciani L; Galassi R
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30979096
[TBL] [Abstract][Full Text] [Related]
60. On the opto-electronic properties of phosphine and thiolate-protected undecagold nanoclusters.
Muniz-Miranda F; Menziani MC; Pedone A
Phys Chem Chem Phys; 2014 Sep; 16(35):18749-58. PubMed ID: 25075579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
